| TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis Z Jiang, SO Lim, M Yan, JL Hsu, J Yao, Y Wei, SS Chang, H Yamaguchi, ... The Journal of clinical investigation 131 (8), 2021 | 170 | 2021 |
| Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4 GN Zhao, P Zhang, J Gong, XJ Zhang, PX Wang, M Yin, Z Jiang, LJ Shen, ... Nature medicine 23 (6), 742-752, 2017 | 143 | 2017 |
| Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer Y Qiu, Y Yang, R Yang, C Liu, JM Hsu, Z Jiang, L Sun, Y Wei, CW Li, D Yu, ... Oncogene 40 (31), 4992-5001, 2021 | 81 | 2021 |
| Hepatic leukocyte immunoglobulin‐like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1‐TRAF6 pathway Y Lu, Z Jiang, H Dai, R Miao, J Shu, H Gu, X Liu, Z Huang, G Yang, ... Hepatology 67 (4), 1303-1319, 2018 | 46 | 2018 |
| Cancer cell metabolism bolsters immunotherapy resistance by promoting an immunosuppressive tumor microenvironment Z Jiang, JL Hsu, Y Li, GN Hortobagyi, MC Hung Frontiers in oncology 10, 1197, 2020 | 39 | 2020 |
| Targeting transmembrane BAX inhibitor motif containing 1 alleviates pathological cardiac hypertrophy KQ Deng, GN Zhao, Z Wang, J Fang, Z Jiang, J Gong, FJ Yan, XY Zhu, ... Circulation 137 (14), 1486-1504, 2018 | 35 | 2018 |
| LILRB4 deficiency aggravates the development of atherosclerosis and plaque instability by increasing the macrophage inflammatory response via NF-κB signaling Z Jiang, JJ Qin, Y Zhang, WL Cheng, YX Ji, FH Gong, XY Zhu, Y Zhang, ... Clinical Science 131 (17), 2275-2288, 2017 | 26 | 2017 |
| Phosphorylation and stabilization of PD-L1 by CK2 suppresses dendritic cell function X Zhao, Y Wei, YY Chu, Y Li, JM Hsu, Z Jiang, C Liu, JL Hsu, WC Chang, ... Cancer Research 82 (11), 2185-2195, 2022 | 23 | 2022 |
| Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation HH Lee, YN Wang, WH Yang, W Xia, Y Wei, LC Chan, YH Wang, Z Jiang, ... Nature communications 12 (1), 2788, 2021 | 13 | 2021 |
| Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex YY Chu, MK Chen, Y Wei, HH Lee, W Xia, YN Wang, C Yam, JL Hsu, ... Nature Cancer 3 (10), 1211-1227, 2022 | 9 | 2022 |
| BMP2K dysregulation promotes abnormal megakaryopoiesis in acute megakaryoblastic leukemia M Wang, T Zhang, X Zhang, Z Jiang, M Peng, Z Huang Cell & Bioscience 10, 1-14, 2020 | 7 | 2020 |
| Ribonuclease 1 enhances antitumor immunity against breast cancer by boosting T cell activation YN Wang, HH Lee, Z Jiang, LC Chan, GN Hortobagyi, D Yu, MC Hung International journal of biological sciences 19 (10), 2957, 2023 | 2 | 2023 |
| PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity P Koller, N Baran, K Harutyunyan, A Cavazos, S Mallampati, RL Chin, ... Journal for immunotherapy of cancer 11 (10), 2023 | 1 | 2023 |
| Dasatinib increases MHCII surface levels and can synergize with anti-PD1 therapy to increase the anti-tumor effect in a pre-clinical Philadelphia chromosome positive acute … P Koller, K Harutyunyan, A Cavazos, N Baran, S Mallampati, R Chin, ... Blood 136, 44, 2020 | 1 | 2020 |
| Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer J Fu, J Ling, CF Li, CL Tsai, W Yin, J Hou, P Chen, Y Cao, Y Kang, Y Sun, ... Nature Communications 15 (1), 3149, 2024 | | 2024 |
| Revitalizing CAR-T cells for TNBC: Targeting phosphorylation of TCF7 to overcome T cell exhaustion Z Jiang, YY Chu, HH Lee, MC Hung, L Yang, C Lin Cancer Research 84 (6_Supplement), 33-33, 2024 | | 2024 |
